Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
CES1	1066	CYCLANDELATE	CHEMBL1480987		DrugBank	2306268
CES1	1066	CHEMBL1237117	CHEMBL1237117		DrugBank	10592235
CES1	1066	[1,4']Bipiperidinyl	CHEMBL174391		DrugBank	10592235
CES1	1066	CHEMBL175543	CHEMBL175543		DrugBank	11992644, 10592235
CES1	1066	CHOLIC ACID	CHEMBL205596		DrugBank	10592235
CES1	1066	CAPECITABINE	CHEMBL1773		PharmGKB
CES1	1066	CHEMBL1234621	CHEMBL1234621		DrugBank
CES1	1066	ISONIAZID	CHEMBL64		PharmGKB
CES1	1066	CLOPIDOGREL	CHEMBL1771		PharmGKB
CES1	1066	LEVOCARNITINE	CHEMBL1149		DrugBank	6509906
CES1	1066	PROBUCOL	CHEMBL608		DrugBank	16292755

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
CES1	rs2244613	T	Dabigatran	metabolism/PK	no		Allele T is not associated with clearance of Dabigatran in healthy individuals as compared to allele G.	32564268	1451207800
CES1	rs8192935	G	Dabigatran	metabolism/PK	no		Allele G is not associated with clearance of Dabigatran in healthy individuals as compared to allele A.	32564268	1451207769
CES1	rs199944431	CG	methylphenidate	dosage	no	No GG individuals observed. This was reported on rs3815589 (now retired and remapped).	Genotype CG is not associated with dose of methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype CC.	24350812	1451158300
CES1	rs1555511231	CT	methylphenidate	efficacy	no	Determined using the Conners' Parent Rating Scale ADHD Index T-score at baseline and week 6 of treatment. No CC individuals observed. This was reported on rs2287194 (now retired and remapped).	Genotype CT is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype TT.	24350812	1451158369
CES1	rs147055479	GG	methylphenidate	dosage	no	The paper reports for retired rs# rs2307244 (C/T), alleles are complemented here.	Genotype GG is not associated with dose of methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG.	24350812	1451158440
CES1	rs147055479	GG	methylphenidate	"dosage","efficacy"	no	Determined using the Conners' Parent Rating Scale ADHD Index T-score at baseline and week 6 of treatment.The paper reports for retired rs# rs2307244 (C/T), alleles are complemented here.	Genotype GG is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG.	24350812	1451158461
CES1	rs1555511231	CT	methylphenidate	dosage	no	No CC individuals observed. This was reported on rs2287194 (now retired and remapped).	Genotype CT is not associated with dose of methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype TT.	24350812	1451158360
CES1	rs199944431	CG	methylphenidate	efficacy	no	Determined using the Conners' Parent Rating Scale ADHD Index T-score at baseline and week 6 of treatment. No GG individuals observed.This was reported on rs3815589 (now retired and remapped).	Genotype CG is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype CC.	24350812	1451158401
CES1	rs71647871	CT	methylphenidate	"dosage","metabolism/PK"	yes	This association was found in the responder group not in the overall cohort (90 responders vs 32 non-responders). The overall cohort showed no association for the categorical analysis nor the dimensional analysis of Inattention and Hyperactivity-Impulsivity score reduction. However, analyzing the daily dose, showed an association for the 5 responder harboring the Glu-allele requiring lower doses of MPH for symptom reduction (0.410 +/- 0.127 vs 0.572 +/- 0.153 mg/kg, t(1,88) = 2.33, p = 0.022).	Genotype CT is associated with decreased dose of methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype CC.	19733552	827923820
CES1	rs71647871	CT	methylphenidate	efficacy	no		Genotype CT is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype CC.	19733552	827923830
CES1	rs12443580	TT	methylphenidate	dosage	no		Genotype TT is not associated with dose of methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes CC + CT.	24350812	1184511750
CES1	rs71647871	T	methylphenidate	metabolism/PK	yes	Metabolism assessed through AUC.	Allele T is associated with decreased metabolism of methylphenidate in healthy individuals as compared to allele C.	28087982	1448573551
CES1	rs2002577	CC	methylphenidate	dosage	no	Determined using the Conners' Parent Rating Scale ADHD Index T-score at baseline and week 6 of treatment.	Genotype CC is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes CG + GG.	24350812	1184511766
CES1	rs2002577	CC	methylphenidate	dosage	no		Genotype CC is not associated with dose of methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes CG + GG.	24350812	1184511738
CES1	rs2307240	CT	methylphenidate	dosage	no		Genotype CT is not associated with dose of methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype CC.	24350812	1184511746
CES1	rs71647871	CT + TT	clopidogrel	metabolism/PK	yes	The AUC of clopidogrel and Cmax of its active metabolite were 67% (P=0.009) and 63% (P=0.017) higher in subjects with the CES1 c.428G/A genotype than in those with the c.428G/G genotype, suggesting reduced clopidogrel hydrolysis to inactive metabolites and increased antiplatelet effects.	Genotypes CT + TT are associated with increased exposure to clopidogrel in healthy individuals as compared to genotype CC.	25704243	1444696308
CES1	rs71647871	CT	enalapril	metabolism/PK	no	This was a fixed-order crossover study with two phases: following overnight fasting participants took a 10 mg dose of quinapril and, after a washout period of at least 1 week, a 10 mg dose of enalapril with 150 ml water in the morning and EDTA-prepared blood samples were drawn before and up to 24 hr, and up to 48 h after ingestion for the determination of the concentrations of quinapril and its metabolite quinaprilat, as well as enalapril and its metabolite enalaprilat. Urine was collected up to 12 h after quinapril and enalapril. Only AUC (0-infinity) and amount excreted in urine of enalaprilat were significantly different between genotype groups. Other PK parameters that were tested and not significantly different were Cmax, Tmax, T(1/2), and renal clearance.	Genotype CT is not associated with clearance of enalapril in healthy individuals as compared to genotype CC.	25919042	1446899459
CES1	rs2244613	GG	Dabigatran	metabolism/PK	yes	Alleles given as A and C. Concentration measured as the trough concentration in plasma. A linear additive effect model was used, with CC associated with a 3% decrease in trough concentrations compared to AA.	Genotype GG is associated with decreased concentrations of Dabigatran in people with Atrial Fibrillation as compared to genotype TT.	27261537	1448100931
CES1	rs8192935	GG	Dabigatran	metabolism/PK	yes	Alleles given as C and T. Concentration measured as the trough concentration in plasma.	Genotype GG is associated with increased concentrations of Dabigatran in people with Atrial Fibrillation as compared to genotypes AA + AG.	27261537	1448100784
CES1	rs200707504	CT	oseltamivir	metabolism/PK	no	Please note that alleles have been complemented to the positive strand.	Genotype CT is associated with increased concentrations of oseltamivir in healthy individuals as compared to genotype TT.	28437488	1448994861
CES1	rs2307240	CT	methylphenidate	dosage	no	Determined using the Conners' Parent Rating Scale ADHD Index T-score at baseline and week 6 of treatment.	Genotype CT is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype CC.	24350812	1184511778
CES1	rs2244613	TT	methylphenidate	dosage	no		Genotype TT is not associated with dose of methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes GG + GT.	24350812	1184511734
CES1	rs2244613	TT	methylphenidate	dosage	no	Determined using the Conners' Parent Rating Scale ADHD Index T-score at baseline and week 6 of treatment.	Genotype TT is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes GG + GT.	24350812	1184511770
CES1	rs2307240	CT + TT	clopidogrel	efficacy	yes	The authors investigated the association between genotypes and several clinical outcomes in patients with acute coronary syndrome who were also taking clopidogrel	Genotypes CT + TT are associated with increased response to clopidogrel in people with Acute coronary syndrome as compared to genotype CC.	28775293	1448640683
CES1	rs71647871	CT + TT	clopidogrel	efficacy	yes	The average inhibition of P2Y12 -mediated platelet aggregation 0-12 h after clopidogrel intake was 19% higher in the c.428G/A carriers than in noncarriers (P=0.036) suggesting the antiplatelet effect of clopidogrel was enhanced in subjects with the CES1 c.428G/A genotype.	Genotypes CT + TT are associated with increased response to clopidogrel in healthy individuals as compared to genotype CC.	25704243	1444696319
CES1	rs71647871	CT	quinapril	metabolism/PK	no	This was a fixed-order crossover study with two phases: following overnight fasting participants took a 10 mg dose of quinapril and, after a washout period of at least 1 week, a 10 mg dose of enalapril with 150 ml water in the morning and EDTA-prepared blood samples were drawn before and up to 24 hr, and up to 48 h after ingestion for the determination of the concentrations of quinapril and its metabolite quinaprilat, as well as enalapril and its metabolite enalaprilat. Urine was collected up to 12 h after quinapril and enalapril. Only AUC (0-infinity) and amount excreted in urine of enalaprilat were significantly different between genotype groups. Other PK parameters that were tested and not significantly different were Cmax, Tmax, T(1/2), and renal clearance.	Genotype CT is not associated with clearance of quinapril in healthy individuals as compared to genotype CC.	25919042	1446899465
CES1	rs71647871	CT	enalapril	metabolism/PK	yes	This was a fixed-order crossover study with two phases: following overnight fasting participants took a 10 mg dose of quinapril and, after a washout period of at least 1 week, a 10 mg dose of enalapril with 150 ml water in the morning and EDTA-prepared blood samples were drawn before and up to 24 hr, and up to 48 h after ingestion for the determination of the concentrations of quinapril and its metabolite quinaprilat, as well as enalapril and its metabolite enalaprilat. Urine was collected up to 12 h after quinapril and enalapril. Only AUC (0-infinity) and amount excreted in urine of enalaprilat were significantly different between genotype groups. Other PK parameters that were tested and not significantly different were Cmax, Tmax, T(1/2), and renal clearance.	Genotype CT is associated with decreased metabolism of enalapril in healthy individuals as compared to genotype CC.	25919042	1446899416
CES1	rs71647871	CT	quinapril	metabolism/PK	no	This was a fixed-order crossover study with two phases: following overnight fasting participants took a 10 mg dose of quinapril and, after a washout period of at least 1 week, a 10 mg dose of enalapril with 150 ml water in the morning and EDTA-prepared blood samples were drawn before and up to 24 hr, and up to 48 h after ingestion for the determination of the concentrations of quinapril and its metabolite quinaprilat, as well as enalapril and its metabolite enalaprilat. Urine was collected up to 12 h after quinapril and enalapril. Only AUC (0-infinity) and amount excreted in urine of enalaprilat were significantly different between genotype groups. Other PK parameters that were tested and not significantly different were Cmax, Tmax, T(1/2), and renal clearance.	Genotype CT is not associated with metabolism of quinapril in healthy individuals as compared to genotype CC.	25919042	1446899452